Table 1 Demographics and clinical characteristics of LN patients

Age* (years)

33.4 ± 10.1

36.6 ± 12.5

48.3 ± 12.5

32.9 ± 7.9

Female, no. (%)

73 (82)

20 (83)

15 (34)

22 (56)

Asian/African American/Hispanic/Caucasia, no.

3/35/37/12

3/33/37/12

2/11/14/17

3/10/14/11

SLEDAI**

10 (6–18)

2 (0–4)

N/A

N/A

rSLEDAI**

8 (4–12)

0 (0–0)

N/A

N/A

Protein-to-creatinine ratio** (mg/mg)

1.73 (0.9–3.4)

0 (0.1–0.2)

1.04 (0.203–2.44)

eGFR** (mL/min/1.73 m²)

64 (34.75–111.5)

69 (27–102.75)

56.5 (34.3–84.5)

Positive ANA/total tested

38/83

11/24

N/A

N/A

Positive anti-dsDNA/total tested

34/89

8/24

N/A

N/A

Hypocomplementemia/total tested

50/89

9/24

N/A

N/A

Renal pathology, no. (%)

I: 0 (0)

I: 0 (0)

DN: 15 (35)

II: 6 (7)

II: 4 (17)

FSGS: 6 (14)

III/ III+V: 22 (25)

III/III+V: 7 (29)

MN: 5 (11)

IV/IV+V: 41 (46)

IV/IV+V: 8 (33)

MN+FSGS: 1 (2)

V: 14 (16)

V: 3 (13)

MCD: 3 (7)

VI: 1 (1)

VI: 0 (0)

ANCA-GN: 6 (13)

Unknown: 5 (6)

Unknown: 2 (8)

Crescent GN: 1 (2)

BANS: 1 (2)

 Hypertension

39 (46)

8 (33)

34 (77)

 Diabetes mellitus

4 (5)

1 (4)

18 (41)

 Hyperlipidemia

36 (40)

4 (17)

26 (60)

 Hypothyroidism

6 (7)

1 (4)

2 (5)

 Pulmonary embolism

7 (8)

2 (8)

3 (7)

 Prednisone

65 (73)

14 (58)

12 (28)

 Cyclophosphamide

9 (10)

0 (0)

1 (2)

 Mycophenolate mofetil

23 (26)

10 (42)

4 (9)

 Azathioprine

6 (7)

4 (17)

0 (0)

 Methotrexate

1 (1)

1 (4)

1 (2)

 Cyclosporine/tacrolimus

1 (1)

2 (8)

1 (2)

 Hydroxychloroquine

43 (48)

17 (71)

1 (2)

 ACE inhibitors/ARB

45 (51)

14 (58)

30 (70)

 Anti-coagulation/platelets

2 (2)

3 (13)

N/A